News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
227,615 Results
Type
Article (7158)
Company Profile (16)
Press Release (220441)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63130)
Career Advice (294)
Deals (14770)
Drug Delivery (28)
Drug Development (36791)
Employer Resources (24)
FDA (6411)
Job Trends (4908)
News (121815)
Policy (11628)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
Academia (567)
Accelerated approval (2)
Adcomms (7)
Allergies (35)
Alliances (14767)
ALS (28)
Alzheimer's disease (599)
Antibody-drug conjugate (ADC) (36)
Approvals (6454)
Artificial intelligence (99)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4608)
BIOSECURE Act (1)
Biosimilars (20)
Biotechnology (18)
Bladder cancer (45)
Brain cancer (14)
Breast cancer (103)
Cancer (1086)
Cardiovascular disease (68)
Career advice (258)
Career pathing (4)
CAR-T (88)
Cell therapy (212)
Cervical cancer (12)
Clinical research (31138)
Collaboration (289)
Compensation (85)
Complete response letters (7)
COVID-19 (722)
CRISPR (18)
C-suite (72)
Cystic fibrosis (37)
Data (1253)
Denatured (1)
Depression (18)
Diabetes (105)
Diagnostics (2227)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (45)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (39)
Earnings (33265)
Editorial (13)
Employer branding (1)
Employer resources (19)
Events (30912)
Executive appointments (236)
FDA (7050)
Featured Employer (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (260)
Gene editing (46)
Generative AI (10)
Gene therapy (125)
GLP-1 (183)
Government (1251)
Grass and pollen (2)
Guidances (34)
Healthcare (6138)
Huntington's disease (4)
IgA nephropathy (14)
Immunology and inflammation (33)
Indications (15)
Infectious disease (783)
Inflammatory bowel disease (58)
Inflation Reduction Act (5)
Influenza (23)
Intellectual property (49)
Interviews (45)
IPO (8030)
IRA (17)
Job creations (570)
Job search strategy (221)
Kidney cancer (7)
Labor market (5)
Layoffs (40)
Leadership (3)
Legal (2104)
Liver cancer (38)
Lung cancer (154)
Lymphoma (75)
Machine learning (1)
Management (7)
Manufacturing (96)
MASH (36)
Medical device (4576)
Medtech (4577)
Mergers & acquisitions (7086)
Metabolic disorders (272)
Multiple sclerosis (37)
NASH (8)
Neurodegenerative disease (25)
Neuropsychiatric disorders (4)
Neuroscience (798)
NextGen: Class of 2025 (1499)
Non-profit (711)
Northern California (1232)
Obesity (136)
Opinion (74)
Ovarian cancer (53)
Pain (35)
Pancreatic cancer (45)
Parkinson's disease (66)
Partnered (5)
Patents (128)
Patient recruitment (58)
Peanut (17)
People (14501)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9937)
Phase II (13700)
Phase III (10275)
Pipeline (715)
Policy (30)
Postmarket research (796)
Preclinical (3616)
Press Release (9)
Prostate cancer (48)
Psychedelics (11)
Radiopharmaceuticals (118)
Rare diseases (155)
Real estate (1004)
Recruiting (7)
Regulatory (9128)
Reports (13)
Research institute (510)
Resumes & cover letters (39)
Rett syndrome (3)
RNA editing (2)
RSV (16)
Schizophrenia (25)
Series A (42)
Series B (30)
Service/supplier (2)
Sickle cell disease (23)
Southern California (1079)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (674)
Stomach cancer (5)
Supply chain (23)
Tariffs (1)
The Weekly (1)
United States (10304)
Vaccines (165)
Venture capitalists (5)
Weight loss (75)
Women's health (6)
Worklife (4)
Date
Today (45)
Last 7 days (213)
Last 30 days (1238)
Last 365 days (15892)
2025 (4279)
2024 (16923)
2023 (19100)
2022 (22240)
2021 (23633)
2020 (21796)
2019 (14439)
2018 (10637)
2017 (11473)
2016 (9554)
2015 (11737)
2014 (8102)
2013 (5878)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (54)
Arkansas (3)
Asia (17529)
Australia (4851)
California (2780)
Canada (1096)
China (229)
Colorado (119)
Connecticut (158)
Delaware (56)
Europe (27941)
Florida (412)
Georgia (68)
Idaho (6)
Illinois (199)
India (20)
Indiana (121)
Japan (88)
Kansas (14)
Kentucky (5)
Louisiana (4)
Maine (36)
Maryland (344)
Massachusetts (1991)
Michigan (51)
Minnesota (102)
Missouri (34)
Montana (11)
Nebraska (8)
Nevada (39)
New Hampshire (36)
New Jersey (964)
New Mexico (3)
New York (887)
North Carolina (386)
North Dakota (2)
Northern California (1232)
Ohio (60)
Oklahoma (1)
Oregon (7)
Pennsylvania (654)
Puerto Rico (6)
Rhode Island (7)
South America (302)
South Carolina (9)
Southern California (1079)
Tennessee (40)
Texas (414)
Utah (65)
Virginia (75)
Washington D.C. (17)
Washington State (337)
West Virginia (2)
Wisconsin (11)
227,615 Results for "imugene limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership
Imugene, Ltd. and Kincell Bio, LLC, announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice manufacturing facility and the transfer of process and analytical development activities to Kincell.
April 16, 2024
·
5 min read
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that enrolment has opened for its expansion study in bile tract cancer (cholangiocarcinoma) patients, having completed the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its cancer-killing virus CF33-hNIS (VAXINIA).
April 15, 2024
·
5 min read
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
Imugene Limited, a clinical stage immuno-oncology company, highlighted recent progress across the company’s immuno-oncology portfolio and provided an update on anticipated upcoming milestones.
February 22, 2024
·
8 min read
Imugene’s oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
April 9, 2024
·
6 min read
BioCapital
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
MaxCyte, Inc. and Imugene announced the signing of a strategic platform license.
January 23, 2024
·
5 min read
Imugene’s CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco.
January 18, 2024
·
3 min read
BioCapital
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
Imugene Ltd and NeoImmuneTech, Inc. announced a strategic collaboration to evaluate Imugene’s allogeneic CAR T, azer-cel, in combination with NIT’s proprietary immune T cell amplifier “Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.
December 11, 2023
·
5 min read
Bio NC
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Precision BioSciences, Inc. (Nasdaq: DTIL) today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.
August 15, 2023
·
10 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Business
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
RenovoRx, Inc and Imugene Ltd today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
July 20, 2023
·
8 min read
1 of 22,762
Next
